The Company continually monitors market factors and industry trends and takes necessary actions to reduce overall costs and improve operational profitability. In the three and nine months ended January 30, 2021, the Company initiated certain restructuring actions in response to the adverse impacts from the COVID-19 pandemic. These actions included plant consolidations and workforce reductions in the Automotive, Industrial and Interface segments. In the three months ended January 30, 2021, the Company recognized $0.7 million of restructuring costs. These charges consist of $0.4 million recorded in cost of products sold and $0.3 million recorded in selling and administrative expenses. In the nine months ended January 30, 2021, the Company recognized $8.3 million of restructuring costs. These charges consist of $5.0 million recorded in cost of products sold and $3.3 million recorded in selling and administrative expenses.

Employee termination benefits are accrued upon the commitment to a termination plan and when the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable. Asset impairment charges relate to the impairment of right-of-use lease assets and equipment. Contract termination costs are recorded when notification of termination is given to the other party. The following is a rollforward of the Company's restructuring activity for the nine months ended January 30, 2021:

					Utilization
(Dollars in Millions)	Accrual as of May 2, 2020		YTD Charges		Cash			Non-cash			Accrual as of January 30, 2021
Employee Termination Benefits	$	0.2	$	7.1	$	(6.5	)	$	—		$	0.8
Asset Impairment Charges		—		0.6		—			(0.6	)		—
Contract Termination Costs		—		0.6		—			—			0.6
Total	$	0.2	$	8.3	$	(6.5	)	$	(0.6	)	$	1.4

	Three Months Ended				Nine Months Ended
	January 30, 2021		February 1, 2020		January 30, 2021		February 1, 2020
(Dollars in Millions)	(13 Weeks)		(14 Weeks)		(39 Weeks)		(40 Weeks)
Automotive	$	0.5	$	0.5	$	6.4	$	0.7
Industrial		—		0.2		0.9		0.4
Interface		—		—		0.7		—
Medical		—		—		—		0.1
Eliminations/Corporate		0.2		0.4		0.3		0.4
Total Restructuring Costs	$	0.7	$	1.1	$	8.3	$	1.6

Estimates of restructuring costs are based on information available at the time such charges are recorded. Due to the inherent uncertainty involved in estimating restructuring costs, actual amounts paid for such activities may differ from amounts initially recorded. Accordingly, the Company may record revisions of previous estimates by adjusting previously established accruals. The Company expects to incur additional restructuring costs of approximately $0.2 million during the current fiscal year related to the initiated restructuring programs and may take additional restructuring actions in future periods based upon market conditions and industry trends.